C4 Therapeutics (CCCC) Expected to Announce Earnings on Thursday

C4 Therapeutics (NASDAQ:CCCC) is projected to post its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect C4 Therapeutics to post earnings of ($0.43) per share for the quarter. Individuals can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, October 30, 2025 at 7:00 AM ET.

C4 Therapeutics (NASDAQ:CCCC) last issued its earnings results on Thursday, August 7th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.01. C4 Therapeutics had a negative return on equity of 53.91% and a negative net margin of 325.88%.The business had revenue of $6.46 million during the quarter, compared to the consensus estimate of $5.24 million. On average, analysts expect C4 Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

C4 Therapeutics Stock Down 7.3%

Shares of NASDAQ CCCC opened at $2.28 on Thursday. C4 Therapeutics has a 52 week low of $1.09 and a 52 week high of $6.52. The business has a 50-day simple moving average of $2.55 and a two-hundred day simple moving average of $1.97. The company has a market cap of $162.27 million, a P/E ratio of -1.44 and a beta of 2.94.

Analysts Set New Price Targets

Several research analysts have commented on the company. Barclays raised their target price on C4 Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Monday, September 22nd. Wells Fargo & Company lifted their price target on C4 Therapeutics from $5.00 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, September 23rd. Wall Street Zen downgraded C4 Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Stephens reiterated an “overweight” rating and set a $6.00 price target on shares of C4 Therapeutics in a research report on Monday, September 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of C4 Therapeutics in a research report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $8.50.

Hedge Funds Weigh In On C4 Therapeutics

Large investors have recently modified their holdings of the company. Wasatch Advisors LP raised its holdings in shares of C4 Therapeutics by 10.4% during the 2nd quarter. Wasatch Advisors LP now owns 7,424,662 shares of the company’s stock valued at $10,617,000 after buying an additional 700,253 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of C4 Therapeutics by 0.9% during the 2nd quarter. Bank of America Corp DE now owns 2,008,004 shares of the company’s stock valued at $2,871,000 after buying an additional 17,180 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of C4 Therapeutics by 8.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 622,720 shares of the company’s stock valued at $996,000 after buying an additional 49,065 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of C4 Therapeutics by 3,816.8% during the 2nd quarter. Jane Street Group LLC now owns 492,612 shares of the company’s stock valued at $704,000 after buying an additional 480,035 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of C4 Therapeutics by 1,039.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 206,177 shares of the company’s stock valued at $295,000 after buying an additional 188,081 shares in the last quarter. 78.81% of the stock is owned by hedge funds and other institutional investors.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.